Genomic profiling of young-onset gBRCA1/2 breast cancer reveals distinct genomic landscapes and therapeutic implications for PARP and CDK4/6 inhibitor selection
Mwangala P. Akamandisa, Mingyi Xia, Wilson Cheah…·Katherine L. Nathanson
This study compares genomic features of gBRCA1 and gBRCA2 breast cancers, finding distinct mutational patterns and therapeutic implications for PARP and CDK4/6 inhibitors.